Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy | Zendy

Ravishankar Ram Mani | Zendy; Xinsheng Teh | Zendy; Tamayanthi Rajakumar | Zendy; KheanLee Goh | Zendy; Alex HwongRuey Leow | Zendy; Bee Hoon Poh | Zendy; Vanitha Mariappan | Zendy; Esaki M. Shankar | Zendy; Mun Fai Loke | Zendy; Jamuna Vadivelu | Zendy

Open Access

Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy

Author(s) -

Ravishankar Ram Mani,

Xinsheng Teh,

Tamayanthi Rajakumar,

KheanLee Goh,

Alex HwongRuey Leow,

Bee Hoon Poh,

Vanitha Mariappan,

Esaki M. Shankar,

Mun Fai Loke,

Jamuna Vadivelu

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky401

Subject(s) - cyp2c19 , clarithromycin , helicobacter pylori , metronidazole , genotype , proton pump inhibitor , gastroenterology , biology , antibiotics , drug resistance , allele , medicine , microbiology and biotechnology , gene , genetics

Eradication of Helicobacter pylori is influenced by susceptibility to antimicrobial agents, elevated bacterial load and degree of acid inhibition, which can be affected by genotypes of drug-metabolizing enzymes [cytochrome P450 (CYP) 2C19 polymorphism]. Theoretically, the choice and dose of proton pump inhibitor may also influence the suppression of H. pylori infection. The CYP2C19 genotype has recently been found to have an impact on peptic ulcer healing, H. pylori eradication and therapeutic efficacy of proton pump inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research